Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
ZBH · NYSE · Healthcare
Fundamental quality
73
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its profitability drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2021 | $6,827M | $402M | $1,356M | $6,691M |
| 2022 | $6,940M | $231M | — | $5,321M |
| 2023 | $7,394M | $1,024M | $1,291M | $5,352M |
| 2024 | $7,679M | $904M | $1,296M | $5,679M |
| 2025 | $8,232M | $705M | $1,473M | $6,927M |
Between 2021 and 2025, revenue went from $6,827M to $8,232M (+21%) and net income went from $402M to $705M (+76%).
Annual figures in U.S. dollars per SEC filings. Net debt is total debt minus cash.
Is Zimmer Biomet Holdings, Inc. a profitable company?
Zimmer Biomet Holdings, Inc. is profitable, with a net margin of 9.1%, though a thin one.
Does Zimmer Biomet Holdings, Inc. have a lot of debt?
Yes, its leverage is high: net debt is 3.08 times its EBITDA.
Is Zimmer Biomet Holdings, Inc. growing?
Its revenue has grown 6.1% annualized in recent years and its earnings per share 47.2%.
Does Zimmer Biomet Holdings, Inc. generate cash?
Yes. It converts about 17.3% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Zimmer Biomet Holdings, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →